Keryx Biopharmaceuticals to Hold Conference Call Tomorrow, November 5, 2013,
at 8:30AM ET to Discuss Top-Line Results from Zerenex(TM) Phase 2 Study of
Non-Dialysis Dependent Chronic Kidney Disease Patients with Elevated Serum
Phosphorus and Iron Deficiency Anemia
NEW YORK, Nov. 4, 2013 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc.
(Nasdaq:KERX) will host a conference call tomorrow, Tuesday, November 5, 2013,
at 8:30am ET to review the top-line results from the Phase 2 study of Zerenex™
(ferric citrate coordination complex) in non-dialysis dependent chronic kidney
disease patients with elevated serum phosphorus and iron deficiency anemia.
Keryx will announce the top-line results tomorrow morning, prior to the call.
Ron Bentsur, Chief Executive Officer of Keryx, will host the call. Geoffrey A.
Block, MD, Director of Clinical Research at Denver Nephrology, Glenn Chertow,
MD, Chief, Division of Nephrology and Professor of Medicine at Stanford
University School of Medicine, and Steven Fishbane, MD, Chief, Division of
Nephrology, Vice President of North Shore-LIJ Health System for Network
Dialysis Services and Director of Clinical Research at North Shore-LIJ
Department of Medicine, Co-Chairmen of the Phase 2 study, will also join the
In addition to the announcement of the top-line results, the Company will
briefly discuss the Company's third quarter financial results and provide a
business outlook for the remainder of 2013.
In order to participate in the conference call, please call 1-877-869-3847
(U.S.), 1-201-689-8261 (outside the U.S.), call-in ID: KERYX. The rebroadcast
of the conference call will be available for replay at http://www.keryx.com,
for a period of 15 days after the call.
About Keryx Biopharmaceuticals, Inc.
Keryx Biopharmaceuticals is focused on the acquisition, development and
commercialization of medically important pharmaceutical products for the
treatment of renal disease. Keryx is developing Zerenex (ferric citrate
coordination complex), an oral, ferric iron-based compound that has the
capacity to bind to phosphate and form non-absorbable complexes. Keryx has
completed a U.S.-based Phase 3 clinical program for Zerenex for the treatment
of hyperphosphatemia (elevated phosphate levels) in patients with chronic
kidney disease on dialysis, conducted pursuant to a Special Protocol
Assessment (SPA) agreement with the Food and Drug Administration (FDA). The
Company's New Drug Application (NDA) is currently under review by the FDA with
an assigned Prescription Drug User Fee Act (PDUFA) goal date of June 7,
2014.The Marketing Authorization Application filing with the European
Medicines Agency (EMA) is pending submission.The Company is also developing
Zerenex in the U.S. for the management of elevated phosphorus and iron
deficiency anemia in patients with stages 3 to 5 non-dialysis dependent
chronic kidney disease.In addition, Keryx's Japanese partner, Japan Tobacco
Inc. and Torii Pharmaceutical Co., Ltd. has filed its New Drug Application for
marketing approval of ferric citrate in Japan for the treatment of
hyperphosphatemia in patients with chronic kidney disease. Keryx is
headquartered in New York City.
CONTACT: Lauren Fischer
Director - Investor Relations
Keryx Biopharmaceuticals, Inc.
Press spacebar to pause and continue. Press esc to stop.